Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disorder and characterized by motor system disorders resulting in loss of dopaminergic (DA) neurons. CXC195, a novel tetramethylpyrazine derivative, has been shown strongest neuroprotective effects due to its anti-apoptotic activity. However, whether CXC195 protects against DA neuronal damage in PD and the mechanisms underlying its beneficial effects are unknown. The purpose of our study was to investigate the potential neuroprotective role of CXC195 and to elucidate its mechanism of action against 6-hydroxydopamine (6-OHDA)-induced mouse model of PD. CXC195 administration improved DA neurodegeneration in PD mice induced by 6-OHDA. Our further findings confirmed treatment of CXC195 at the dose of 10 mg/kg significantly inhibited the apoptosis by decreasing the level of cleaved caspase-3 and Bax, and increasing the level of Bcl-2 in 6-OHDA-lesioned mice. Meanwhile, 6-OHDA also decreased the amount of phosphorylated Akt while increased GSK-3β activity (the amount of phosphorylated GSK-3β at Ser9 was decreased) which was prevented by CXC195. Wortmannin, a specific PI3K inhibitor, dramatically abolished the changes induced by CXC195. Our study firstly demonstrated that CXC195 protected against DA neurodegeneration in 6-OHDA-induced PD model by its anti-apoptotic properties and PI3K/Akt/GSK3β signaling pathway was involved in it.
Similar content being viewed by others
References
Basu S, Je G, Kim YS (2015) Transcriptional mutagenesis by 8-oxodG in alpha-synuclein aggregation and the pathogenesis of Parkinson’s disease. Exp Mol Med 47:e179. doi:10.1038/emm.2015.54
Nutt JG, Wooten GF (2005) Clinical practice. Diagnosis and initial management of Parkinson’s disease. N Engl J Med 353(10):1021–1027. doi:10.1056/NEJMcp043908
Wright JW, Kawas LH, Harding JW (2015) The development of small molecule angiotensin IV analogs to treat Alzheimer’s and Parkinson’s diseases. Prog Neurobiol 125:26–46. doi:10.1016/j.pneurobio.2014.11.004
Connolly BS, Lang AE (2014) Pharmacological treatment of Parkinson disease: a review. JAMA 311(16):1670–1683. doi:10.1001/jama.2014.3654
Hensley K, Harris-White ME (2015) Redox regulation of autophagy in healthy brain and neurodegeneration. Neurobiol Dis 84:50–59. doi:10.1016/j.nbd.2015.03.002
Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, Halliday G (2010) Missing pieces in the Parkinson’s disease puzzle. Nat Med 16(6):653–661. doi:10.1038/nm.2165
Li YH, Fu HL, Tian ML, Wang YQ, Chen W, Cai LL, Zhou XH, Yuan HB (2016) Neuron-derived FGF10 ameliorates cerebral ischemia injury via inhibiting NF-kappaB-dependent neuroinflammation and activating PI3K/Akt survival signaling pathway in mice. Sci Rep 6:19869. doi:10.1038/srep19869
Orike N, Middleton G, Borthwick E, Buchman V, Cowen T, Davies AM (2001) Role of PI 3-kinase, Akt and Bcl-2-related proteins in sustaining the survival of neurotrophic factor-independent adult sympathetic neurons. J Cell Biol 154(5):995–1005. doi:10.1083/jcb.200101068
Jope RS, Johnson GV (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29(2):95–102. doi:10.1016/j.tibs.2003.12.004
Blum D, Torch S, Nissou MF, Benabid AL, Verna JM (2000) Extracellular toxicity of 6-hydroxydopamine on PC12 cells. Neurosci Lett 283(3):193–196
Chen G, Bower KA, Ma C, Fang S, Thiele CJ, Luo J (2004) Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J 18(10):1162–1164. doi:10.1096/fj.04-1551fje
Guo B, Xu D, Duan H, Du J, Zhang Z, Lee SM, Wang Y (2014) Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson’s disease in vitro and in vivo. Biol Pharm Bull 37(2):274–285
Lu C, Zhang J, Shi X, Miao S, Bi L, Zhang S, Yang Q, Zhou X, Zhang M, Xie Y, Miao Q, Wang S (2014) Neuroprotective effects of tetramethylpyrazine against dopaminergic neuron injury in a rat model of Parkinson’s disease induced by MPTP. Int J Biol Sci 10(4):350–357. doi:10.7150/ijbs.8366
Yan S, Chen L, Wei X, Cheng L, Kong L, Liu X, Zhang X, Liu H (2015) Tetramethylpyrazine analogue CXC195 ameliorates cerebral ischemia–reperfusion injury by regulating endothelial nitric oxide synthase phosphorylation via PI3K/Akt signaling. Neurochem Res 40(3):446–454. doi:10.1007/s11064-014-1485-x
Ou Y, Dong X, Liu XY, Cheng XC, Cheng YN, Yu LG, Guo XL (2010) Mechanism of tetramethylpyrazine analogue CXC195 inhibition of hydrogen peroxide-induced apoptosis in human endothelial cells. Biol Pharm Bull 33(3):432–438
Chen L, Wei X, Hou Y, Liu X, Li S, Sun B, Liu X, Liu H (2014) Tetramethylpyrazine analogue CXC195 protects against cerebral ischemia/reperfusion-induced apoptosis through PI3K/Akt/GSK3beta pathway in rats. Neurochem Int 66:27–32. doi:10.1016/j.neuint.2014.01.006
Deng L, Guo X, Zhai L, Song Y, Chen H, Zhan P, Wu J, Liu X (2012) Ligustrazine derivatives. Part 4: design, synthesis, and biological evaluation of novel ligustrazine-based stilbene derivatives as potential cardiovascular agents. Chem Biol Drug Des 79(5):731–739. doi:10.1111/j.1747-0285.2012.01332.x
Ng SS, Tsao MS, Nicklee T, Hedley DW (2001) Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 7(10):3269–3275
Lou H, Jing X, Wei X, Shi H, Ren D, Zhang X (2014) Naringenin protects against 6-OHDA-induced neurotoxicity via activation of the Nrf2/ARE signaling pathway. Neuropharmacology 79:380–388. doi:10.1016/j.neuropharm.2013.11.026
Zhu KY, Fu Q, Leung KW, Wong ZC, Choi RC, Tsim KW (2011) The establishment of a sensitive method in determining different neurotransmitters simultaneously in rat brains by using liquid chromatography–electrospray tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 879(11–12):737–742. doi:10.1016/j.jchromb.2011.02.011
Zhang K, Tarazi FI, Davids E, Baldessarini RJ (2002) Plasticity of dopamine D4 receptors in rat forebrain: temporal association with motor hyperactivity following neonatal 6-hydroxydopamine lesioning. Neuropsychopharmacology 26(5):625–633. doi:10.1016/S0893-133X(01)00404-3
Liu H, Wei X, Chen L, Liu X, Li S, Liu X, Zhang X (2013) Tetramethylpyrazine analogue CXC195 protects against cerebral ischemia/reperfusion injury in the rat by an antioxidant action via inhibition of NADPH oxidase and iNOS expression. Pharmacology 92(3–4):198–206. doi:10.1159/000354722
Blandini F, Armentero MT, Martignoni E (2008) The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord 14(Suppl 2):S124–S129. doi:10.1016/j.parkreldis.2008.04.015
Tsuchioka A, Oana F, Suzuki T, Yamauchi Y, Ijiro T, Kaidoh K, Hiratochi M (2015) Duration of drug action of dopamine D2 agonists in mice with 6-hydroxydopamine-induced lesions. Neuroreport 26(18):1126–1132. doi:10.1097/WNR.0000000000000484
Hernandes MS, Santos GD, Cafe-Mendes CC, Lima LS, Scavone C, Munhoz CD, Britto LR (2013) Microglial cells are involved in the susceptibility of NADPH oxidase knockout mice to 6-hydroxy-dopamine-induced neurodegeneration. PloS One 8(9):e75532. doi:10.1371/journal.pone.0075532
Toyoshi T, Ukai M, Kameyama T (1995) Intrastriatal injection of opioid receptor agonists inhibits apomorphine-induced behavior in 6-hydroxydopamine-treated mice. Eur J Pharmacol 294(2–3):637–643
Schwarting RK, Huston JP (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50(2–3):275–331
Hudson JL, van Horne CG, Stromberg I, Brock S, Clayton J, Masserano J, Hoffer BJ, Gerhardt GA (1993) Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 626(1–2):167–174
Vila M, Przedborski S (2003) Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 4(5):365–375. doi:10.1038/nrn1100
Nataraj J, Manivasagam T, Justin Thenmozhi A, Essa MM (2016) Neuroprotective effect of asiatic acid on rotenone-induced mitochondrial dysfunction and oxidative stress-mediated apoptosis in differentiated SH-SYS5Y cells. Nutr Neurosci. doi:10.1080/1028415X.2015.1135559
Maiese K (2016) Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders. Br J Clin Pharmacol 82(5):1245–1266. doi:10.1111/bcp.12804
Levy OA, Malagelada C, Greene LA (2009) Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps. Apoptosis 14(4):478–500. doi:10.1007/s10495-008-0309-3
Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, Mouatt-Prigent A, Turmel H, Srinivasan A, Ruberg M, Evan GI, Agid Y, Hirsch EC (2000) Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson’s disease. Proc Natl Acad Sci USA 97(6):2875–2880. doi:10.1073/pnas.040556597
Cha GH, Kim S, Park J, Lee E, Kim M, Lee SB, Kim JM, Chung J, Cho KS (2005) Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. Proc Natl Acad Sci USA 102(29):10345–10350. doi:10.1073/pnas.0500346102
Mirzayans R, Andrais B, Kumar P, Murray D (2016) The growing complexity of cancer cell response to DNA-damaging agents: caspase 3 mediates cell death or survival?. Int J Mol Sci. doi:10.3390/ijms17050708
Ullah F, Ali T, Ullah N, Kim MO (2015) Caffeine prevents d-galactose-induced cognitive deficits, oxidative stress, neuroinflammation and neurodegeneration in the adult rat brain. Neurochem Int 90:114–124. doi:10.1016/j.neuint.2015.07.001
Wei X, He S, Wang Z, Wu J, Zhang J, Cheng Y, Yang J, Xu X, Chen Z, Ye J, Chen L, Lin L, Xiao J (2014) Fibroblast growth factor 1attenuates 6-hydroxydopamine-induced neurotoxicity: an in vitro and in vivo investigation in experimental models of parkinson’s disease. Am J Transl Res 6(6):664–677
Greene LA, Levy O, Malagelada C (2011) Akt as a victim, villain and potential hero in Parkinson’s disease pathophysiology and treatment. Cell Mol Neurobiol 31(7):969–978. doi:10.1007/s10571-011-9671-8
Amiri E, Ghasemi R, Moosavi M (2016) Agmatine protects against 6-OHDA-induced apoptosis, and ERK and Akt/GSK disruption in SH-SY5Y cells. Cell Mol Neurobiol 36(6):829–838. doi:10.1007/s10571-015-0266-7
Das G, Misra AK, Das SK, Ray K, Ray J (2012) Role of tau kinases (CDK5R1 and GSK3B) in Parkinson’s disease: a study from India. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2010.10.016
Kalinderi K, Fidani L, Katsarou Z, Clarimon J, Bostantjopoulou S, Kotsis A (2011) GSK3beta polymorphisms, MAPT H1 haplotype and Parkinson’s disease in a Greek cohort. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2009.05.007
Hernandez-Baltazar D, Mendoza-Garrido ME, Martinez-Fong D (2013) Activation of GSK-3beta and caspase-3 occurs in Nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine. PloS One 8(8):e70951. doi:10.1371/journal.pone.0070951
Zhang LQ, Sa F, Chong CM, Wang Y, Zhou ZY, Chang RC, Chan SW, Hoi PM, Yuen Lee SM (2015) Schisantherin A protects against 6-OHDA-induced dopaminergic neuron damage in zebrafish and cytotoxicity in SH-SY5Y cells through the ROS/NO and AKT/GSK3beta pathways. J Ethnopharmacol 170:8–15. doi:10.1016/j.jep.2015.04.040
Acknowledgements
This work was financially supported by National Natural Science Foundation of China (No. 81571171) and Shandong Province Science and Technology Plan (No. 2014GSF118003).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there are no conflicts of interest.
Rights and permissions
About this article
Cite this article
Chen, L., Cheng, L., Wei, X. et al. Tetramethylpyrazine Analogue CXC195 Protects Against Dopaminergic Neuronal Apoptosis via Activation of PI3K/Akt/GSK3β Signaling Pathway in 6-OHDA-Induced Parkinson’s Disease Mice. Neurochem Res 42, 1141–1150 (2017). https://doi.org/10.1007/s11064-016-2148-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-016-2148-x